Login Register Cart 0
Generic placeholder image

Recent Patents on Nanotechnology

Editor-in-Chief

ISSN (Print): 1872-2105
ISSN (Online): 2212-4020

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Formulation Development and In vitro-Ex vivo Assessment of Simvastatin Niosomal Buccal Films

Author(s): Sudhakar Beeravelli, Vyasamurthy Akondi and Madhavi Nimmathota*

Volume 16, Issue 3, 2022

Published on: 31 May, 2021

Page: [235 - 249] Pages: 15

DOI: 10.2174/1872210515666210531112006

Price: $65

Abstract

Aim: The present study aims to develop and characterize simvastatin niosomal film for effective buccal delivery.

Methods: Simvastatin niosomes were developed by film hydration technique followed by highpressure homogenization using chiller at 5°C. The simvastatin niosomes were characterized for various physicochemical parameters, and simvastatin plain and niosomal films were prepared using PEO as the base by solvent casting technique.

Results: From the simvastatin niosomes suspension, the percentage assay was found in the range of 96% to 103%, particles size was found in the range of 112nm to 308nm, the zeta potential was found in the range of -9mV to -25.8mV, the %EE was found in the range of 28% to 91% and the in vitro permeation was found in the range of 43.41% to 98% respectively. The niosomal film shown superior results as compared to simvastatin plain film. The FTIR and DSC confirm the compatibility among the existed excipients.

Conclusion: Niosomes alter the physicochemical properties of simvastatin by the buccal route. The prolonged permeation (96.12% up to 24hrs) of simvastatin was observed from niosomes film across the porcine buccal cavity due to the presence of CPE in the composition, which would be useful for effective buccal delivery.

Keywords: Niosomes, Span 60, Cholesterol, Permeation, buccal films, Chemical permeation enhancer.

« Previous Next »
Graphical Abstract

[1]
Chinna Reddy P, Chaitanya KS, Madhusudan Rao Y. A review on bioadhesive buccal drug delivery systems: current status of formulation and evaluation methods. Daru 2011; 19(6): 385-403.
[PMID: 23008684]
[2]
Rossi S, Sandri G, Caramella CM. Buccal drug delivery: A challenge already won? Drug Discov Today Technol 2005; 2(1): 59-65.
[http://dx.doi.org/10.1016/j.ddtec.2005.05.018] [PMID: 24981756]
[3]
Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 2018; 143: 155-70.
[http://dx.doi.org/10.1016/j.brainresbull.2018.10.009] [PMID: 30449731]
[4]
Chenthamara D, Subramaniam S, Ramakrishnan SG, et al. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res 2019; 23: 20.
[http://dx.doi.org/10.1186/s40824-019-0166-x] [PMID: 31832232]
[5]
Raju KK, Sudhakar B, Ramana Murthy KV. Factorial design studies and biopharmaceutical evaluation of simvastatin loaded solid lipid nanoparticles for improving the oral bioavailability. ISRN Nanotechnology 2014.
[6]
Available from: https://pubchem.ncbi.nlm.nih.gov/compound/54454 accessed on 23/07/2014 [Accessed on 23/07/2014]
[7]
Gilhotra RM, Ikram M, Srivastava S, Gilhotra N. A clinical perspective on mucoadhesive buccal drug delivery systems. J Biomed Res 2014; 28(2): 81-97.
[PMID: 24683406]
[8]
Aungst BJ. Oral mucosal permeation enhancement: Possibilities and limitationsOral mucosal drug delivery. New York: Marcel Dekker, Inc 1996; pp. 65-83.
[9]
El-Samaligy MS, Afifi NN, Mahmoud EA. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. Int J Pharm 2006; 308(1-2): 140-8.
[http://dx.doi.org/10.1016/j.ijpharm.2005.11.006] [PMID: 16356669]
[10]
Abd El Azim H, Nafee N, Ramadan A, Khalafallah N. Liposomal buccal mucoadhesive film for improved delivery and permeation of water-soluble vitamins. Int J Pharm 2015; 488(1-2): 78-85.
[http://dx.doi.org/10.1016/j.ijpharm.2015.04.052] [PMID: 25899288]
[11]
Lankalapalli S, Tenneti VS. Formulation and evaluation of rifampicin liposomes for buccal drug delivery. Curr Drug Deliv 2016; 13(7): 1084-99.
[http://dx.doi.org/10.2174/1567201813666151221145617] [PMID: 26687256]
[12]
Jin BZ, Dong XQ, Xu X, Zhang FH. Development and in vitro evaluation of mucoadhesive patches of methotrexate for targeted delivery in oral cancer. Oncol Lett 2018; 15(2): 2541-9.
[PMID: 29434971]
[13]
Rahamathulla M, H v G, Veerapu G, et al. Characterization, optimization, in vitro and in vivo evaluation of simvastatin proliposomes, as a drug delivery. AAPS PharmSciTech 2020; 21(4): 129.
[http://dx.doi.org/10.1208/s12249-020-01666-4] [PMID: 32405982]
[14]
Zidan AS, Hosny KM, Ahmed OA, Fahmy UA. Assessment of simvastatin niosomes for pediatric transdermal drug delivery. Drug Deliv 2016; 23(5): 1536-49.
[PMID: 25386740]
[15]
Bartelds R, Nematollahi MH, Pols T, et al. Niosomes, an alternative for liposomal delivery. PLoS One 2018; 13(4): e0194179.
[http://dx.doi.org/10.1371/journal.pone.0194179] [PMID: 29649223]
[16]
Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol 2005; 18(5): 209-19.
[http://dx.doi.org/10.1159/000086666] [PMID: 16015019]
[17]
Shi B, Fang C, Pei Y. Stealth PEG-PHDCA niosomes: Effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci 2006; 95(9): 1873-87.
[http://dx.doi.org/10.1002/jps.20491] [PMID: 16795003]
[18]
Barenholz Y, Amselem S, Goren D, et al. Stability of liposomal doxorubicin formulations: Problems and prospects. Med Res Rev 1993; 13(4): 449-91.
[http://dx.doi.org/10.1002/med.2610130404] [PMID: 8361255]
[19]
Madhavi N, Sudhakar B, Reddy KVNS, Ratna JV. Design by optimization and comparative evaluation of vesicular gels of etodolac for transdermal delivery. Drug Dev Ind Pharm 2019; 45(4): 611-28.
[http://dx.doi.org/10.1080/03639045.2019.1569030] [PMID: 30712433]
[20]
Sudhakar B, Varma JN, Murthy KV. Formulation, characterization and ex vivo studies of terbinafine HCl liposomes for cutaneous delivery. Curr Drug Deliv 2014; 11(4): 521-30.
[http://dx.doi.org/10.2174/1567201810666140109113830] [PMID: 24410098]
[21]
Mehta SK, Jindal N, Kaur G. Quantitative investigation, stability and in vitro release studies of anti-TB drugs in Triton niosomes. Colloids Surf B Biointerfaces 2011; 87(1): 173-9.
[http://dx.doi.org/10.1016/j.colsurfb.2011.05.018] [PMID: 21640561]
[22]
Ge X, Wei M, He S, Yuan WE. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics 2019; 11(2): 55.
[http://dx.doi.org/10.3390/pharmaceutics11020055] [PMID: 30700021]
[23]
Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products
[24]
Zidan AS, Rahman Z, Khan MA. Product and process understanding of a novel pediatric anti-HIV tenofovir niosomes with a high-pressure homogenizer. Eur J Pharm Sci 2011; 44(1-2): 93-102.
[http://dx.doi.org/10.1016/j.ejps.2011.06.012] [PMID: 21726640]

Rights & Permissions Print Cite
Article Metrics
16
1
© 2024 Bentham Science Publishers | Privacy Policy